Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 1,574 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Period B Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn if the Study Medicine Called Itraconazole and if Food Changes How the Body Processes the Other Study Medicine Called PF 07258669 in Older Adults or Healthy Adults

NCT06706869
View directory record Official record
Conditions
Healthy
Interventions
PF-07258669, Itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Nov 9, 2026, 5:15 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Bioavailability and Food Effect of SACT-1 and Edurant® Tablets in Healthy Adult Volunteers

NCT05358756
View directory record Official record
Conditions
Healthy Subject
Interventions
SACT-1, EDURANT 25Mg Tablet
Drug
Lead sponsor
Aptorum International Limited
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Nov 9, 2026, 5:15 PM EST
Completed Phase 2 Interventional Results available

Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women

NCT02046148
View directory record Official record
Conditions
GBS Disease, Streptococcus Agalactiae
Interventions
GBS trivalent vaccine, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Aurora, Colorado • Baltimore, Maryland • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Nov 9, 2026, 5:15 PM EST
Completed Phase 2 Interventional Results available

Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis

NCT03996291
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Tolebrutinib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
8
States / cities
Cullman, Alabama • Maitland, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Nov 9, 2026, 5:15 PM EST
Withdrawn Phase 1 Interventional

CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)

NCT03768310
View directory record Official record
Conditions
Non-hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Interventions
CD19.CAR-multiVST for Group A, CD19.CAR-multiVST for Group B
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2040
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Nov 9, 2026, 5:15 PM EST
Enrolling by invitation Not applicable Interventional

Harnessing Digital Medicine to Improve Allergic Rhinitis Management in Primary Care (DMAR)

NCT06603935
View directory record Official record
Conditions
Allergic Rhinitis, Sinusitis
Interventions
QHSLab Digital Tools (AME and ARIS)
Other
Lead sponsor
QHSLab, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Nov 9, 2026, 5:15 PM EST
Terminated Phase 2 Interventional Results available

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)

NCT04888585
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
ABBV-154, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
101
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Fullerton, California + 89 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Nov 9, 2026, 5:15 PM EST
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00058292
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, Carmustine, cytarabine, etoposide, melphalan, peripheral blood stem cell transplantation, yttrium Y 90 ibritumomab tiuxetan
Biological · Drug · Procedure + 1 more
Lead sponsor
Northwestern University
Other
Eligibility
17 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Nov 9, 2026, 5:15 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A TQTc Study for Omaveloxolone

NCT05927649
View directory record Official record
Conditions
Health Adult Subjects
Interventions
Omaveloxolone, Moxifloxacin
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Nov 9, 2026, 5:15 PM EST
Completed Phase 1 Interventional

A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the Medicine

NCT06642571
View directory record Official record
Conditions
Obesity
Interventions
NNC0519-0130 B, NNC0519-0130 C
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Nov 9, 2026, 5:15 PM EST
Completed Phase 3 Interventional Results available

A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes

NCT05478252
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide J, Semaglutide B
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
55
States / cities
Gilbert, Arizona • Costa Mesa, California • La Mesa, California + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Nov 9, 2026, 5:15 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease

NCT00901498
View directory record Official record
Conditions
Alzheimer's Disease, Healthy
Interventions
BMS-708163
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 7, 2011 · Synced Nov 9, 2026, 5:15 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult Volunteers

NCT02663999
View directory record Official record
Conditions
Healthy
Interventions
diazepam nasal spray
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Nov 9, 2026, 5:15 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral Formulations

NCT06996886
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5004
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Nov 9, 2026, 5:15 PM EST
Completed Phase 2 Interventional Results available

PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma

NCT00054665
View directory record Official record
Conditions
B-Cell Lymphoma
Interventions
PS-341, Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone, Filgrastim
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2012 · Synced Nov 9, 2026, 5:15 PM EST
Terminated Phase 1 Interventional Results available

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

NCT02784795
View directory record Official record
Conditions
Solid Tumor, Breast Cancer, Colon Cancer, Cholangiocarcinoma, Soft Tissue Sarcoma
Interventions
LY3039478, Taladegib, Abemaciclib, Cisplatin, Gemcitabine, Carboplatin, LY3023414
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Miami, Florida • Detroit, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Nov 9, 2026, 5:15 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Effect of Tablet Formulation and Food on PF-07104091 in Healthy Participants

NCT05431153
View directory record Official record
Conditions
Healthy
Interventions
Single dose of PF-07104091 as Tablet Formulation A (Treatment A), Single dose of PF-07104091 as Tablet Formulation B (Treatment B), Single dose of PF-07104091 as Tablet Formulation C (Treatment C), Single dose of PF-07104091 as Tablet Formulation D (Treatment D), Single dose of PF-07104091 as Tablet Formulation C (Treatment E)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Nov 9, 2026, 5:15 PM EST
Completed Phase 4 Interventional

Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design

NCT01713777
View directory record Official record
Conditions
Epilepsy
Interventions
Lamotrigine Generic "A", Lamotrigine generic "B"
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
8
States / cities
Birmingham, Alabama • Des Moines, Iowa • Kansas City, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Nov 9, 2026, 5:15 PM EST
Completed Phase 2 Interventional Results available

Bracing and Strengthening for Posterior Tibial Tendon Dysfunction

NCT00756457
View directory record Official record
Conditions
Posterior Tibial Tendon Dysfunction
Interventions
Bracing, Strengthening exercises, Stretching exercises
Device · Other
Lead sponsor
Ithaca College
Other
Eligibility
40 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Nov 9, 2026, 5:15 PM EST
Recruiting Phase 2 Interventional

Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis

NCT07841977
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Seladelpar, PTM Seladelpar, Cilofexor Dose B, PTM Cilofexor Dose A, PTM Cilofexor Dose B, Cilofexor Dose A
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
4
States / cities
Colorado Springs, Colorado • Lakewood Rch, Florida • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 9, 2026, 5:15 PM EST
Completed Phase 1 Interventional

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With Schizophrenia

NCT01559272
View directory record Official record
Conditions
Schizophrenia
Interventions
Paliperidone IR (Period 1), Paliperidone palmitate F015 (Panel A: treatment group 1), Paliperidone palmitate F015 (Panel A: treatment group 2), Paliperidone palmitate F015 (Panel B: treatment group 1), Paliperidone palmitate F015 (Panel B: treatment group 2), Paliperidone palmitate F015 (Panel B: treatment group 3), Paliperidone palmitate F015 (Panel B: treatment group 4), Paliperidone palmitate F015 (Panel B: treatment group 5), Paliperidone palmitate F016, Paliperidone palmitate F015 (Panel D: treatment group 1), Paliperidone palmitate F015 (Panel D: treatment group 2), Paliperidone palmitate F015 (Panel D: treatment group 3), Paliperidone palmitate F015 (Panel D: treatment group 4)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
10
States / cities
Little Rock, Arkansas • Cerritos, California • Garden Grove, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Nov 9, 2026, 5:15 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Broadband Sound and Sleep

NCT05774977
View directory record Official record
Conditions
Noise Exposure
Interventions
Aviation Noise Only (AN), Pink noise only, 50 dBA (BN50), Aviation Noise With Earplugs (AN+EP), Aviation Noise With Pink Noise, 40 dBA (AN+BN40), Aviation Noise With Pink Noise, 50 dBA (AN+BN50)
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Nov 9, 2026, 5:15 PM EST
Completed Phase 1 Interventional

A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients

NCT00821054
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Buffalo, New York • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Nov 9, 2026, 5:15 PM EST
Completed Not applicable Interventional Results available

Improving Depression Management Through Peer Support

NCT00777205
View directory record Official record
Conditions
Depression
Interventions
Telephone-based peer support, Enhanced Usual Care
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
4
States / cities
Ann Arbor, Michigan • Battle Creek, Michigan • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Nov 9, 2026, 5:15 PM EST